OBJECTIVE: We aimed to explore whether cancer patients urgently referred to a cancer patient pathway (CPP) (CPP referred) by a general practitioner report experiences of pre-diagnosis cancer care differently than patients not referred to a CPP (non-CPP referred). METHODS: Data were collected from cross-sectional questionnaire surveys among cancer patients and their GPs and linked to National registries. Poisson regression was used to generate adjusted prevalence ratios (PR) to compare reported experiences. RESULTS: The study included 2,256 individuals. CPP referred patients reported more positive overall experiences of the pre-diagnosis phase (p < 0.001). Overall, CPP referred patients were 21% more likely than non-CPP referred patients to report a positive experience after adjustment for case-mix, comorbidity, disposable household income and educational level (PR = 1.21 [95% CI: 1.11-1.30]). The difference decreased to 14% when adjusted for Quality Deviations (PR = 1.14 [95% CI: 1.06-1.23]) and to 11% when adjusted for diagnostic interval (PR = 1.11 [95% CI: 1.02-1.20]). CONCLUSION: Our findings suggest that CPP referred cancer patients have better experiences of pre-diagnosis cancer care compared to non-CPP referred patients. A substantial part of the difference could be attributed to shorter diagnostic intervals and/or the absence of quality deviations among CPP patients, which reveals the potential for generally improving cancer patients' experiences by seamless and optimised diagnostic pathways.
OBJECTIVE: We aimed to explore whether cancerpatients urgently referred to a cancerpatient pathway (CPP) (CPP referred) by a general practitioner report experiences of pre-diagnosis cancer care differently than patients not referred to a CPP (non-CPP referred). METHODS: Data were collected from cross-sectional questionnaire surveys among cancerpatients and their GPs and linked to National registries. Poisson regression was used to generate adjusted prevalence ratios (PR) to compare reported experiences. RESULTS: The study included 2,256 individuals. CPP referred patients reported more positive overall experiences of the pre-diagnosis phase (p < 0.001). Overall, CPP referred patients were 21% more likely than non-CPP referred patients to report a positive experience after adjustment for case-mix, comorbidity, disposable household income and educational level (PR = 1.21 [95% CI: 1.11-1.30]). The difference decreased to 14% when adjusted for Quality Deviations (PR = 1.14 [95% CI: 1.06-1.23]) and to 11% when adjusted for diagnostic interval (PR = 1.11 [95% CI: 1.02-1.20]). CONCLUSION: Our findings suggest that CPP referred cancerpatients have better experiences of pre-diagnosis cancer care compared to non-CPP referred patients. A substantial part of the difference could be attributed to shorter diagnostic intervals and/or the absence of quality deviations among CPP patients, which reveals the potential for generally improving cancerpatients' experiences by seamless and optimised diagnostic pathways.
Authors: Minjoung M Koo; Georgios Lyratzopoulos; Annie Herbert; Gary A Abel; Rachel M Taylor; Julie A Barber; Faith Gibson; Jeremy Whelan; Lorna A Fern Journal: JAMA Netw Open Date: 2020-09-01
Authors: George N Okoli; Otto L T Lam; Viraj K Reddy; Leslie Copstein; Nicole Askin; Anubha Prashad; Jennifer Stiff; Satya Rashi Khare; Robyn Leonard; Wasifa Zarin; Andrea C Tricco; Ahmed M Abou-Setta Journal: BMJ Open Date: 2021-11-09 Impact factor: 2.692
Authors: Samuel William David Merriel; Stephanie Archer; Alice S Forster; David Eldred-Evans; John McGrath; Hashim Uddin Ahmed; Willie Hamilton; Fiona M Walter Journal: BMJ Open Date: 2022-07-26 Impact factor: 3.006
Authors: B Danckert; H Jensen; N L Christensen; A Z Falborg; H Frederiksen; G Lyratzopoulos; S McPhail; A F Pedersen; J Ryg; L A Thomsen; P Vedsted Journal: BMC Cancer Date: 2022-08-19 Impact factor: 4.638
Authors: Vicky L M N Soomers; Ingrid M E Desar; Lonneke V van de Poll-Franse; Michiel A J van de Sande; Jacco J de Haan; Cornelis Verhoef; Ingeborg J H Vriens; Winan J van Houdt; Johannes J Bonenkamp; Winette T A van der Graaf; Olga Husson Journal: Cancers (Basel) Date: 2020-07-28 Impact factor: 6.639